No active substance abuse or history of prior substance abuse that may interfere with study compliance. This is an observational longitudinal inpatient and outpatient study of HIV genetic variation in drug na ve patients. Patients will have the option of starting therapy any time after the first 10 days on study. Patients who opt not to start therapy can be followed for up to 18 months. Patients who have decided to initiate therapy will be followed for a total of 2 years.
Protocol includes teaching sessions to address adherence to antiviral medicines.
All patients will need to undergo an initial screening visit to determine eligibility. If eligible they will return for a History and Physical visit not less than 13 and not more than 28 days from screening visit. Enrollment will occur 2 weeks after the History and Physical visit. The first 10 daysof study will be as an inpatient followed by weekly visits for 16 weeks, then monthly visits for 14 months. In unusual circumstances, the inpatient period can be arranged as outpatient monitoring.